Details
Stereochemistry | ACHIRAL |
Molecular Formula | C14H12F7N5S |
Molecular Weight | 415.332 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=NC2=NC(=NN2C(NC3=CC=C(C=C3)S(F)(F)(F)(F)F)=C1)C(C)(F)F
InChI
InChIKey=OIZSVTOIBNSVOS-UHFFFAOYSA-N
InChI=1S/C14H12F7N5S/c1-8-7-11(26-13(22-8)24-12(25-26)14(2,15)16)23-9-3-5-10(6-4-9)27(17,18,19,20)21/h3-7,23H,1-2H3
Molecular Formula | C14H12F7N5S |
Molecular Weight | 415.332 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DSM265 is an experimental antimalarial that selectively inhibits the parasite dihydroorotate dehydrogenase (DHODH). DSM265 is the first DHODH inhibitor to reach clinical development for treatment of malaria. DSM265 is highly selective toward DHODH of the malaria parasite Plasmodium, efficacious against both blood and liver stages of P. falciparum, and active against drug-resistant parasite isolates. The only possible DSM265-related adverse event was a moderate transient elevation in serum bilirubin.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3486 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21696174 |
PubMed
Title | Date | PubMed |
---|---|---|
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. | 2017 Jun |
|
DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum. | 2019 Apr |
|
Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265. | 2019 Jan 11 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28363637
Single dose of 400 mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:44:49 GMT 2023
by
admin
on
Sat Dec 16 11:44:49 GMT 2023
|
Record UNII |
0Q42P4YI6B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
598417
Created by
admin on Sat Dec 16 11:44:49 GMT 2023 , Edited by admin on Sat Dec 16 11:44:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
51347395
Created by
admin on Sat Dec 16 11:44:49 GMT 2023 , Edited by admin on Sat Dec 16 11:44:49 GMT 2023
|
PRIMARY | |||
|
0Q42P4YI6B
Created by
admin on Sat Dec 16 11:44:49 GMT 2023 , Edited by admin on Sat Dec 16 11:44:49 GMT 2023
|
PRIMARY | |||
|
1282041-94-4
Created by
admin on Sat Dec 16 11:44:49 GMT 2023 , Edited by admin on Sat Dec 16 11:44:49 GMT 2023
|
PRIMARY | |||
|
DB12397
Created by
admin on Sat Dec 16 11:44:49 GMT 2023 , Edited by admin on Sat Dec 16 11:44:49 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR | |||
|
TARGET ORGANISM->INHIBITOR |
DSM265 displayed maximum antimalarial effects at 3 × EC50 and above, requiring a 24- to 48-hour lag phase before parasite killing. At 1 × EC50, DSM265 parasite killing was further delayed (96-hour lag phase).
EC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||